论文部分内容阅读
终末期肝病是急慢性肝损伤的晚期阶段,通常广泛累及肝实质细胞,使肝组织再生能力下降,造成肝功能失代偿并最终导致肝功能衰竭,严重影响着患者的预后。因残存肝细胞不足,常规的内科保肝治疗效果不佳,病死率很高。原位肝移植作为目前终末期肝病最有效的治疗措施,因肝源紧缺、移植排斥反应需长期应用免疫抑制剂及费用昂贵等因素而限制了其广泛应用。于是研究者们开始将目光投向再生医学领域,试图寻找更为行之有效的治疗方
End-stage liver disease is an advanced stage of acute and chronic liver injury, usually involving the extensive hepatic parenchymal cells, reducing the regenerative capacity of liver tissue, causing hepatic decompensation and eventually leading to liver failure, which seriously affects the prognosis of patients. Due to the lack of residual liver cells, conventional medical treatment of liver damage is not good, high mortality. Orthotopic liver transplantation as the most effective treatment for end-stage liver disease, due to lack of liver, transplant rejection need long-term use of immunosuppressive agents and expensive and other factors that limit its wide application. So researchers began to look to regenerative medicine, trying to find more effective treatment